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Orexin 2 Receptor Antagonists 
from Prefrontal Cortical Circuitry 
to Rodent Behavioral Screens
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Abstract
Orexin is a neuropeptide contained in neurons from several hypothalamic nuclei 
that project throughout the forebrain analogously to monoamines synthesized by 
brainstem nuclei. Orexin, like 5-hydroxytryptamine (5-HT), norepinephrine (NE), 
dopamine (DA), histamine and acetylcholine (ACh) exerts prominent effects on 
the sleep-wake cycle of all mammals. Activation of the orexin2 receptor appears 
to induce spontaneous excitatory synaptic currents (EPSCs) on layer V pyramidal 
neurons due to release of glutamate from thalamocortical terminals similar to acti-
vation of 5-HT2A and α1-adrenergic receptors. Layer V pyramidal cells are the major 
descending output cell in the prefrontal cortex with projections to the thalamus, 
striatum, amygdala, brainstem and spinal cord. In keeping with salient modulation 
of prefrontal cortical physiology, orexin2 receptor antagonists exert similar effects 
to 5-HT2A receptor antagonists in suppressing hallucinogen (e.g., DOI)-induced 
head twitches and producing antidepressant-like effects on the differential-
reinforcement-of-low-rate 72-s (DRL 72-s) schedule of reinforcement. Currently, 
there is both negative and some preliminary positive evidence that blocking orexin2 
receptors may result in antidepressant efficacy in patients with major depressive 
disorder. Overall, the treatment of mood disorders is an additional potential indica-
tion for orexin receptor antagonists beyond simply improving sleep.
Keywords: antidepressant drug screens, excitatory postsynaptic potential currents 
(EPSCs), DOI-induced head twitches, differential-reinforcement-of-low-rate 72-s 
(DRL 72-s) behavior, LSN2424100, layer V pyramidal neurons, prefrontal cortex, 
thalamocortical axons
1. Introduction
Only approximately 50–60% of patients experience an antidepressant response 
when treated with selective reuptake inhibitors (SSRIs) or serotonin-norepinephrine 
reuptake inhibitors (SNRIs) [1–3]. Even those patients that do respond often continue 
to experience residual symptoms such as insomnia and cognitive dysfunction [4–7]. 
Thus, novel antidepressant medications are needed that treat a broader expanse 
of symptoms or are effective in patients that have failed several different classes of 
antidepressants drugs.
The primary well-documented augmentation treatment for depressed patients 
already on SSRIs or SNRIs are atypical antipsychotics (aripiprazole, quetiapine, 
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risperidone or olanzapine) and less so for mirtazapine/mianserin [8–12]. The 
common pharmacological action shared by these medications is blockade of 5-HT2A 
receptors [13]. Blockade of 5-HT2A receptors may also be a key pharmacological 
feature for most tricyclic antidepressant drugs which explain their greater anti-
depressant efficacy compared to SSRIs [14–17]. However, side effects especially 
problematic for augmentation of SSRIs/SNRIs with atypical antipsychotic drugs are 
weight gain and extrapyramidal symptoms. Thus, discovery of a drug targeted on 
key neurocircuitry modulated by 5-HT2A receptors is one strategy to develop a novel 
antidepressant medication.
Given that pathophysiology of mood disorders appears to involve the prefrontal 
cortex and associated macrocircuits, an obvious candidate brain region to pro-
vide a context for 5-HT2A receptor blockade at augmenting the effects of SSRIs/
SNRIs is the prefrontal cortex [18–21]. In particular, layer V pyramidal neurons 
can effectively modulate important cortical circuits (including corticothalamic, 
corticostriatal, cortico-amydalar and cortico-brainstem) that impact mood, cogni-
tion/executive function, sleep and appetite [22, 23]. One aspect of 5-HT2A receptor 
function largely restricted to layer V pyramidal cells is increasing the frequency 
of spontaneous excitatory postsynaptic currents/potentials (EPSC/EPSPs) onto 
the dendritic branches [24]. This effect appears to be mediated by AMPA receptor 
stimulation of directly on the layer V pyramidal cells [24, 25]. Lesion studies have 
suggested that 5-HT2A receptor activation is releasing glutamate from thalamocorti-
cal terminals arising from the “non-specific” midline and intralaminar thalamic 
nuclei [26, 27]. There appear to be hot spots in layer I and layer Va where focal 
5-HT-induced release of glutamate sensitive to the sodium channel blocker tetrodo-
toxin (TTX) occurs, although an amplification of postsynaptic currents, including 
TTX-sensitive sodium currents [24]. A number of Gi/Go-coupled GPCRs (including 
mGlu2, mGlu4, μ-opioid, adenosine A1 receptors) also suppresses 5-HT- or DOI-
induced glutamate release from these terminals [28–33]. Several other Gq/G11-
coupled GPCRs (α1-adrenergic receptors and mGlu5 receptors) also appear to induce 
glutamate release onto layer V pyramidal neurons that are suppressed by the sodium 
channel blocker TTX, μ-opioid agonists, and AMPA receptor antagonists [34, 35]. 
This rich pharmacological modulation of 5-HT2A receptor-mediated electrophysi-
ological effects on dendritic integration for the principle output neurons in the 
prefrontal cortex provides heuristic promise for drug discovery efforts with respect 
to major psychiatric disease, including mood disorders and schizophrenia [36, 37].
The increase in spontaneous EPSC/EPSPs upon layer V pyramidal cells induced 
by 5-HT2A receptor activation may be associated with other electrophysiological, 
biochemical and behavioral effects involving the medial prefrontal cortex (mPFC). 
On an electrophysiological level, electrical stimulation of the white matter below 
the cortex appears to result in an induction of “late” EPSC/EPSPs during washout 
after application of 5-HT or when the phenethylamine hallucinogen DOI is bath-
applied to the cortical slice [38]. These late EPSCs are also suppressed by a range of 
neurotransmitter receptors that suppress spontaneous 5-HT-induced EPSCs such 
as agonists for mGlu2, μ-opioid, and adenosine A1 receptors [30, 32]. There are 
also some differences between these two electrophysiological responses as NMDA 
receptor stimulation appears important for the electrical stimulation/DOI-evoked 
responses unlike the spontaneous 5-HT-induced EPSC/EPSPs [39].
Secondly, systemic DOI administration also induces a range of immediate-early 
gene-like signals in the prefrontal cortex/neocortex that are also suppressed by 
activation of mGlu2 autoreceptors and appear dependent on glutamate release from 
thalamocortical terminals [40–45]. This effect of prefrontal cortical 5-HT2A recep-
tor activation is relatively sparsely studied compared to the electrophysiological or 
behavioral sequelae.
3Orexin 2 Receptor Antagonists from Prefrontal Cortical Circuitry to Rodent Behavioral Screens
DOI: http://dx.doi.org/10.5772/intechopen.82544
Third, either systemic administration or local prefrontal cortical administration 
of agonists for 5-HT2A receptors induces a robust increase in the frequency of head 
twitches (a behavior infrequently observed under baseline condition) [46, 47]. 
Agonists or positive allosteric modulators of mGlu2, mGlu4, μ-opioid, adenosine A1 
receptors also suppress DOI-induced head twitches [28, 31, 48–52]. Naturally, these 
head twitches induced by direct 5-HT2A receptor agonists are also suppressed by 
a number of antidepressant drugs that potently block 5-HT2A receptors or down-
regulate 5-HT2A receptors such as mirtazapine [53], mianserin [54–57], trazodone 
[55, 58–60], nefazodone [58, 61] and tricyclic antidepressants [55, 57, 62–68] Some 
of the tricyclic antidepressants are active only with chronic daily administration. 
While the antidepressant and monoamine oxidase inhibitor (MAOI) tranylcypro-
mine does not directly bind to 5-HT2A receptors, chronic daily administration of 
this antidepressant has been found to suppress 5-methoxy-N,N-dimethyltrypt-
amine-induced head twitches under conditions associated with a down-regulation 
of 5-HT2A receptors [63]. The clinical lore regarding μ-opioid receptor agonists and 
potential antidepressant action is intriguing in light of effects for this class of drugs 
on DOI-induced head twitches have been discussed elsewhere [36].
Finally, an argument was advanced recently that the basis for detecting antide-
pressant-like drug effects on the operant differential-reinforcement-of-low-rate 
72-s (DRL 72-s) schedule may be related to the biology of a range of neurotrans-
mitter systems that interact with the 5-HT2A receptor in the prefrontal cortex to 
modulate motor impulsivity [69, 70]. As expected from the similar effects of 5-HT2A 
receptor antagonists compared to mGlu2 receptor positive allosteric modulators 
(PAMs) and also to adenosine A1 receptor agonists for the prefrontal electrophysi-
ology discussed above, 5-HT2A receptor antagonists, mGlu2 receptor PAMs and 
adenosine A1 receptor agonists all test similar to known antidepressant drugs in rats 
performing under the DRL 72-s schedule [51, 71–77].
The underlying thesis of this chapter is that understanding how other neu-
rotransmitter systems interact with 5-HT2A receptors in the medial prefrontal cor-
tex on an electrophysiological, biochemical and behavioral scale may help discover 
novel antidepressant drugs. Orexin (OX) receptor agonists/antagonists appear to 
be one such neurotransmitter system that interacts with critical biological aspects 
of 5-HT2A receptor activation/blockade in thalamocortical pathways influencing 
the principle output (layer V pyramidal cells) of the prefrontal cortex in a manner 
suggesting that OX2 receptor antagonists are putative antidepressant medications.
2. Orexin-2 receptor blockade and putative antidepressant action
The orexins are two peptide neurotransmitters produced in several nuclei within the  
lateral hypothalamus which are intimately involved in arousal and reward [78]. The 
name “orexin” was originally coined from the Greek word “orexis” when the orexin/
hypocretin peptides were studied for effects on appetite. However, the more salient 
biological aspect of the orexin system later was realized to be altering sleep and 
arousal. More specifically, mutations of genes for the orexin-2 (OX2) receptor, orexin 
peptides, and loss of orexin-containing hypothalamic cell bodies were demon-
strated to be the genetic cause of narcolepsy in canines, mice and humans. The first 
approved medication targeting the orexin system, suvorexant, blocks both orexin-1 
(OX1) and OX2 receptors as a dual orexin receptor antagonist (DORA) and is indi-
cated for the treatment of insomnia [78, 79]. Several other DORAs have been shown 
to be efficacious in treating primary insomnia [80–82]. The overlapping and diverg-
ing distribution for the OX1 and OX2 mRNA and protein has inspired several decades 
of past/ongoing research exploring these receptors for sleep, arousal, feeding, 
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alcohol and drug self-administration, stress, anxiety and depression models [83].  
The involvement of OX2 receptors in arousal together with the presence of OX2 
receptor mRNA in the non-specific midline and intralaminar thalamic nuclei and 
the interactions of the orexin system with brainstem nuclei with overlapping mono-
amine projections makes the OX2 receptor an especially interesting target for mood 
disorder therapeutics [78, 83]. As discussed below, OX2 or hypocretin-2 receptor 
blockade appears to be a mechanism of action that provides a means of testing the 
hypothesis discussed above where a drug appropriately modifying multiple levels 
of biological effects for 5-HT2A receptor activation in the mPFC would be a putative 
antidepressant medication.
Electrophysiological effects of OX2 receptor activation in the prefrontal cortex 
appear to parallel certain effects of 5-HT2A receptor activation when recording 
from layer V pyramidal neurons. The orexin-B (hypocretin-2) peptide was found to 
increase spontaneous EPSC/EPSPs in layer V pyramidal neurons of the prefrontal 
cortex that were blocked by postsynaptic AMPA receptor antagonists as well as by 
TTX and u-opioid agonists on the presynaptic side similar to the case for 5-HT2A 
receptor stimulation [84]. Experiments to delineate the origin of afferents in the 
PFC from which orexin induced glutamate release from suggested that the cells of 
origin were in the midline and intralaminar thalamic nuclei [84]. Further, the rela-
tive potency for orexin-B compared to orexin-A (hypocretin-1) at inducing spon-
taneous OX-induced EPSCs/EPSPs in PFC layer V pyramidal cells is similar to that 
found in the intralaminar and midline thalamic nuclei with OX2, not OX1, receptor 
responses [84–86]. The tetrodotoxin sensitivity of the orexin-induced EPSCs/
EPSPs is in keeping with earlier studies suggesting that thalamocortical projections 
from these “non-specific” thalamic nuclei associated with arousal were prone to 
the generation of terminal spikes as previously suggested [87, 88]. This dependence 
on thalamocortical pathways originating in the midline and intralaminar thalamic 
nuclei and terminating in layers I and Va of the prefrontal cortex is consistent with 
features for the spontaneous 5-HT-induced EPSCs/EPSPs [26, 27]. One difference 
between OX-induced spontaneous EPSCs and 5-HT-induced EPSCS is that OX does 
not appear to induce postsynaptic depolarization (consistent with absence of OX2 
mRNA in layer V pyramidal cells) unlike the case for 5-HT2A receptor activation in 
the majority of layer V pyramidal cells [84, 89]. However, studies characterizing the 
ability of orexin-B induced EPSCs/EPSPs to be blocked with selective OX2 receptor 
antagonists or selective OX1 receptor antagonists would be useful to unambiguously 
identify the OX receptor subtype involved in this response.
Limited work has been done exploring effects of OX2 receptor antagonists on 
immediate early gene (IEG-like) responses in the prefrontal cortex. However, the 
OX2 receptor antagonist LSN2424100 did suppress restraint stress-induced increases 
in c-Fos protein expression without having any effects on baseline Fos protein 
expression in the home cage [90]. These effects of the OX2 receptor antagonist 
LSN2424100 on restraint stress-induced increases Fos expression in the prelimbic 
cortex are similar to an effect of the mGlu2 receptor agonist LY354740 on restraint 
stress-induced increases in Fos expression [45]. As discussed above, 5-HT2A receptor 
agonists induce a number of immediate IEG-like responses in the prefrontal cortex. 
Activation of mGlu2 receptors appears to suppress the DOI-induced increases in a 
number of IEG-like responses in the prefrontal cortex [40, 41, 44, 91].
Modulation of 5-HT2A receptor agonist-induced head twitches is a behavioral 
measure that is suppressed by a range of antidepressants blocking/regulating 
5-HT2A receptors as discussed above; these DOI-induced head twitches are also 
suppressed by the selective OX2 receptor antagonist LSN2424100 (Figure 1). 
LSN2424100 possesses approximately 200-fold functional OX2 receptor antago-
nist activity at both human recombinant OX2 vs. OX1 receptors or rat OX2 vs. OX1 
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receptors [90]. Administration of LSN2424100 (10 mg/kg, i.p.) 30 min prior to 
administration of DOI (3 mg/kg, i.p.) with behavioral observations beginning 
5 min later for a 30 min period resulted in over a 67% statistically significant reduc-
tion in the frequency of DOI-induced head twitches in CD-1 mice (n = 8/group;  
Figure 1) using conditions/methods/statistical analyses reported elsewhere in 
greater detail [52]. Head twitches were observed in 8/8 vehicle/DOI treated mice 
but in only 3/8 LSN2424100/DOI treated mice (p < 0.05, Fisher’s Exact Test). This 
experiment demonstrating that a Gq/G11-coupled GCPR OX2 receptor antagonist 
(like 5-HT2A receptor antagonists) suppress DOI-induced head twitches fits in with 
evidence that agonists or positive allosteric modulators of Gi/Go-coupled GCPRs 
(mGlu2, mGlu4, adenosine A1, and μ-opioid receptors) similarly suppress DOI-
induce head twitches [28, 31, 48, 50, 52, 92, 93]. Thus, the effects of these drugs on 
spontaneous EPSCs/EPSPs upon layer V pyramidal neuron apical dendrites in layers 
I and Va of the prefrontal cortex all produce directionally consistent effects on DOI-
induced head twitches [37]. These results imply that adequate orexin, glutamate, 
adenosine and endogenous opioid release is present from or onto thalamocortical 
afferents under the in vivo experimental conditions employed to engender salient 
changes in dendritic integration of the principle output layer V pyramidal cells.
OX2 receptor antagonists also appear to modulate at least certain aspects of execu-
tive function mediated by the prefrontal cortex, namely impulsivity and biasing oper-
ant responding for DRL schedules in rodents [69, 90]. The OX2 receptor antagonist 
LSN2424100 increased reinforcers obtained and decreased total responses by Sprague-
Dawley rats performing under a DRL 72-s schedule of reinforcement (Figure 2)  
[90]. These antidepressant-like responses were largely replicated in wild-type CD-1 
mice and OX1 receptor knockout mice responding on a DRL 36-s schedule of rein-
forcement rate [90]. However, no changes in the reinforcement rate or response rate 
Figure 1. 
The effect of (±)-DOI (3 mg/kg, i.p.) and the selective OX2 receptor antagonist LSN2424100 (10 mg/kg, i.p.) 
on head twitches in CD-1 wild-type mice observed for 30 min following drug administration. LSN2424100 was 
administered 30 min prior to DOI. Each bar represents the mean (± SEM) of eight mice. Significantly different 
from the mean number of head twitches for the vehicle/DOI group, * p < 0.05. Significantly different from the 
number of mice displaying head twitches for the vehicle/DOI group, # p < 0.05 by the Fisher exact test.
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were observed in OX2 receptor knockout mice when testing LSN2424100 doses up 
to twice as large as those used for wild-type and OX1 receptor knockout mice [90]. A 
similar antidepressant-like profile was observed in rats, wild-type CD-1 mice, and 
OX1 receptor KO mice with the non-selective OX1/OX2 receptor antagonist almorexant 
[90]. In contrast, a selective OX1 receptor antagonist failed to produce an antidepres-
sant-like response in rats performing on a DRL 72-s schedule or wild type mice or 
OX2 receptor knockout mice responding on a DRL 36-s schedule [90]. However, the 
well-established tricyclic antidepressant drug imipramine tested as expected in these 
experiments as a positive control (e.g., antidepressant-like effects) in Sprague-Dawley 
rats, wild-type mice, OX1 receptor knockout mice, or OX2 receptor KO mice trained to 
lever press under a DRL 72-s schedule (rats) or a DRL 36-s (mice) schedule.
3. Clinical trials with orexin receptor antagonists in patients with MDD
Thus far only a single small double-blind, placebo-controlled, diphenhydr-
amine-controlled, parallel group, phase 1b/2a trial of a selective OX2 receptor 
antagonist, JNJ-42847922/MIN-202 or seltorexant, has been conducted [94]. 
Figure 2. 
The antidepressant-like effect of LSN2424100 on male Sprague-Dawley rats (n = 7) stably performing under 
a DRL 72-s schedule. The top graph shows the effects of LSN2424100 (3–30 mg, i.p.) and imipramine (10 mg/
kg, i.p.) on the number of reinforcers obtained after vehicle/drug was administered 1 hour prior to the daily 
session. The bottom graph shows the effect of LSN2424100 (3–30 mg, i.p.) and imipramine (10 mg/kg, i.p.) on 
the total number of responses. The dotted line shows the control reinforcement and response rate and * denotes 
data points significantly different from control (p < 0.05) (this figure was adapted from data presented by Fitch 
et al. [90]).
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Only 47 men and women with a diagnosis of MDD (DSM-IV) were randomized 
to received either diphenhydramine, 25 mg q.d. (n = 13), seltorexant, 20 mg 
q.d. (n = 22) or placebo (n = 12) for 10 nights. Sleep polysomnography was also 
performed to provide objective assessment of improvements on sleep. There were 
improvements from baseline in the seltorexant treatment group for the HAMD-17 
total score (−3.6 points) as well as the HAM-17 adjusted total score accounting 
for sleep improvement in addition to changes in the HAMD-6 item score (−1.5 
points). This resulted in effect sizes of −0.48, −0.55 and − 1.05 for the OX2 receptor 
antagonist compared to placebo. However, one caveat is that the subjects assigned to 
the histamine H1 receptor antagonist diphenhydramine showed highly comparable 
improvement compared to placebo as did seltorexant. To answer these questions/
concerns, a phase 2b randomized, double-blind parallel group, placebo-controlled, 
adaptive dose-finding trial for seltorexant adjunctive treatment to antidepres-
sants scheduled to enroll about 280 adult subjects at 85 US, European, Russian and 
Japanese sites began in September 2017 (NCT03227224).
The only other MDD clinical trial for an OX receptor antagonist was negative 
[95]. Filorexant (MK-6096), a dual orexin receptor antagonist, was evaluated in a 
6-week, double-blind, placebo-controlled, parallel-group phase 2a proof-of-concept 
trial where subjects with MDD were randomized 1:1 to once-daily oral filorexant 
10 mg or matching placebo. Subjects on antidepressants continued to take their 
prescribed antidepressant for the duration of the trial. This study was stopped 
after enrolling 129 (40%) of a planned 326 subjects. Less than a 1 point numerical 
improvement was observed for filorexant compared to placebo using the mean 
change from baseline to week 6 MADRS total score. Exploratory analyses also 
failed to reveal statistically significant changes in the Insomnia Severity Index (ISI). 
Regarding safety, there were no deaths, drug-related serious adverse events (SAEs) 
and only one discontinuation due to AEs in both treatment groups. There were no 
other problematic safety issues reported.
This negative filorexant MDD study may be related to an issue of inadequate 
power as the planned study was designed with 80% power to detect a 3.5-point 
difference between treatments with a 2-sided 5% level of significance and a fully 
enrolled trial. However, the enrollment of only 129 subjects while using 61 sites 
(United States, Canada, Finland, France, Germany, Norway and Sweden) speaks 
to the recruitment challenges in this study. The dose chosen for this MDD trial 
appears reasonable based on positive effects reported for filorexant in a phase 2 
randomized, double-blind, placebo-controlled adaptive crossover polysomnogra-
phy dose-ranging study evaluating approximately 80 subjects each at nightly doses 
of 2.5, 5 and 10 mg [81]. All doses showed significant effects on sleep efficiency and 
wakefulness after persistent sleep onset while the two higher doses demonstrated 
significant effects on sleep onset. Filorexant was also well tolerated in this insomnia 
trial as well [81].
Preclinical results suggest that the combined OX1/OX2 receptor antagonism 
should not have compromised potential antidepressant action in patients with 
MDD. Namely, the OX1/OX2 receptor antagonist almorexant acted similarly to the 
OX2 receptor antagonist LSN2424100 and the known tricyclic antidepressant imip-
ramine in rats and mice performing on DRL 72-s or DRL 36-s schedules [90]. In 
addition, the non-selective OX receptor antagonist almorexant also tested similarly 
to known antidepressants in mice subjected to unpredictable chronic mild stress 
(UCMS) and then evaluated with the tail suspension test, the resident-intruder 
test, and the elevated plus maze [96]. However, opposing antidepressant-like and 
“pro-depressant”-like effects were observed in OX1 and OX2 receptor knockout 
mice, respectively, studied with the forced swim paradigm [97]. In this same study, 
the selective OX1 receptor antagonist SB-334867 also exerted an antidepressant like 
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Figure 3. 
The model where activation of 5-HT2A or OX2 receptors depolarizes and releases glutamate from non-specific 
thalamocortical inputs to layer I and Va of the apical dendrites from layer V pyramidal neurons. The majority 
of 5-HT2A receptors, apart from a minority of presynaptic receptors and those on GABAergic interneurons, are 
present on and also directly depolarize layer V pyramidal neurons. Other glutamatergic receptors (mGlu2 and 
mGlu4), μ-opioid receptors and adenosine A1 receptors that suppress the EPSCs/EPSPs induced by activation 
of 5-HT2A and OX2 receptors appear to be present on non-specific thalamocortical afferents. This circuitry 
(with additional positive modulator receptor such as mGlu5 and NK3 receptors and also additional negative 
modulators such as β2-adrenergic receptors) appears to underlie a similar valence of action for all these 
receptors for a behavior mediated by activation of 5-HT2A receptors in the prefrontal cortex, DOI-induced 
head twitches. This circuitry also appears to underlie impulsive behavior (DRL 72-s behavior) where a similar 
valence of GPCR mediated effects appears to drive antidepressant-like effects on this screening behavior as 
DOI-induced head twitches and 5-HT-induced EPSCs.
effect in the forced swim test. No data has been published suggesting that selec-
tive OX2 receptor antagonists test as antidepressants in rodent forced swim tests. 
Nevertheless, the balance of data are consistent with the hypothesis that adequate 
blockade of both OX1 and OX2 receptors, or OX2 receptors alone, should improve 
depressive symptoms in patients with MDD.
4. Conclusions
Activation of 5-HT2A receptors or OX2 receptors appears to induce glutamate 
release from thalamocortical terminals with cell bodies originating in the midline 
and intralaminar thalamic nuclei when recording from prefrontal cortical layer 
V pyramidal neurons (Figure 3). This 5-HT and orexin-B-induced glutamate 
release appears to dependent action potentials in the presynaptic terminals judging 
from the TTX-induced blockade of the 5-HT- or orexin-induced EPSC/EPSPs as 
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suggested previously for non-specific thalamocortical axons. Apical dendritic layer 
V pyramidal AMPA receptors appear to be activated postsynaptic to the thalamic 
terminals. The 5-HT or DOI-induced spontaneous EPSCs/EPSPs or DOI/electrically 
evoked EPSC/EPSPs also appear suppressed by mGlu2, mGlu4, adenosine A1, 5-HT-1-like 
and β2-adrenergic receptors.
Future work is required to establish that orexin-B-induced glutamate release 
from non-specific thalamic afferents is also suppressed by mGlu2, mGlu4, adenosine 
A1, 5-HT-1-like and β2-adrenergic receptors. Blockade of OX2 and 5-HT2A receptors 
also both appear to suppress DOI-induced head twitches, a behavioral response 
that appears to be mediated by activation of prefrontal cortical 5-HT2A receptors. 
A selective OX2 receptor antagonist tested similar to the tricyclic antidepressant 
imipramine in rats and mice responding under an operant DRL 72-s schedule of 
reinforcement. Another question for future preclinical research with rodent DRL 
behavior is whether blockade of OX2 receptors is additive/synergistic with tricyclic 
antidepressants or SSRIs in the same manner as blockade of 5-HT2A receptors. The 
ongoing clinical antidepressant trial with the OX2 receptor antagonist seltorexant 
are important to understanding whether the circuitry involving orexin-containing 
cells in the hypothalamus together with orexin-containing axon terminals in the 
intralaminar and midline thalamic nuclei and the prefrontal cortex are necessary 
and sufficient by themselves to augment the antidepressant effects of tricyclic 
antidepressants and SSRIs. If this ongoing and other clinical antidepressant trials 
with selective OX2 receptor antagonists or additional adequately powered clinical 
trials testing OX1/OX2 receptor antagonists are negative, then future work will be 
required to begin to ask whether additional actions of OX2 receptor antagonists 
in other circuitry are functionally opposed to the brainstem/thalamic/prefrontal 
cortical circuits.
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